Table 2.

Ongoing Phase III Studies With Potential to Change Standard of Care in CLL

Study	Treatment Comparison	Treatment Status	Age Group (years)
CLL12	Ibrutinib v placebo	High risk, aymptomatic	≥ 18
RESONATE II	CLB v ibrutinib (crossover)	Symptomatic, untreated	≥ 65
A041202	BR v ibrutinib plus rituximab v ibrutinib (crossover)	Symptomatic, untreated	≥ 65
E1912	FCR v IR	Symptomatic, untreated	< 70
NCT01980888	BR plus placebo v BR plus idelalisib	Symptomatic, untreated	≥ 18
NCT01980875	Idelalisib plus rituximab v placebo plus rituximab or idelalisib plus CLB v placebo plus CLB	Symptomatic, untreated	≥ 65
CLLM1	Lenaldiomide v placebo for consolidation after initial therapy	Consolidation after first treatment	≥ 18
RESONATE	Ofatumumab v ibrutinib	Relapsed	≥ 18
NCT01611090	BR plus placebo v BR plus ibrutinib	Relapsed	≥ 18
NCT01569295	BR plus placebo v BR plus idelalisib	Relapsed	≥ 18
NCT02005471	ABT199 plus rituximab v BR	Relapsed	≥ 18

Abbreviations: BR, bendamustine plus rituximab; CLB, chlorambucil; CLL, chronic lymphocytic leukemia; FCR, fludarabine, cyclophosphosphamide, and rituximab; IR, ibrutinib plus rituximab; RESONATE, A Phase III Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia; RESONATE II, A Multicenter, Open-Label, Phase III Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 Versus Chlorambucil in Patients 65 Years or Older With Treatment-Naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.